Eyecarrot Granted US Patent for Extension of Binovi(tm) Screening Technology

Tags: Healthcare

February 19, 2019 / TheNewswire / Toronto, Ontario - Eyecarrot Innovations Corp (TSX-V: EYC, OTCQB: EYCCF) is pleased to announce that the United States Patent and Trademark Office has issued US Patent 9,504,380 to the company covering a system and method for assessing human visual processing. This proprietary technology allows for the accurate measurement of the degree and speed of vergence facility, as well as other important measurements of human visual processing performance. With visual processing issues affecting almost 1 in 4 people globally, demand for quick and easy testing is of greater importance than ever before.

"Building out our IP portfolio and adding further protection to the BinoviTM Platform is an ongoing process. To have patented testing in place for identification of issues related to potential concussions/brain injuries, misdiagnosis of ADHD, and all general binocular vision disorders is a substantial milestone for the company. Expanding and integrating this screening data will help impact both scalability and revenue as it represents significant time savings and efficacy to the end user." Commented CEO Adam Cegielski.

BinoviTM is positioned to be the global leader in how we develop the skills associated with human visual processing. Baseline testing/screening through easy to use technology and apps will allow the company to address a problem that effects hundreds of millions of people. Quick and easy screening will significantly complement what has already been developed with the BinoviTM platform. BinoviTM Screening is currently in private beta as testing continues, and the company expects its' release in 2019.

An accurate, well-functioning and responsive vergence system is important in almost every aspect of human life, since over 40% of the brain's neurons are used in visual processing. In order to view visual stimulus accurately a person must use their accommodative system, which changes the shape of the lens in the eye to focus the image on the retina, and the vergence system, which is the system responsible for moving the eyes so that they are properly aimed at the object being viewed. Although both the accommodative and vergence systems are used to view an object, current testing does not isolate or stress the vergence system sufficiently.

"Speed of stereopsis and vergence facility are very likely two of the most sensitive metrics to oculomotor dysfunction. Combining the two may well represent an excellent combination of speed and high sensitivity / specificity in the detection of visual dysfunction cases requiring rehabilitative intervention. This is not only the case in concussion cases or visual enhancement strategies in sports, but also in paediatric reading difficulty cases as shown in our research1". Commented Dr. Patrick Quaid, PhD.

1. Quaid & Simpson (2013). Graefes Archives of Clinical & Experimental Ophthalmology.

Eyecarrot's proprietary screening technology will form an integral part of the BinoviTM platform, which enables a world-class patient experience by seamlessly combining software, hardware, data, and expert knowledge of vision care professionals. Using the BinoviTM platform, professionals are able to record and track vision performance issues, such as vergence insufficiency, and provide patients with the ultimate in expert video-guided instruction for vision-led motor activities that exercise and enhance the human visual processing system.

With over 4000 existing customers globally, Eyecarrot is excited to bring modern technology advancements to these current and new customers via the Binovi(TM) platform.

About Eyecarrot

Eyecarrot's goal is to power a global, data-driven, expert therapeutic network to transform how human Oculomotor Sensory performance is diagnosed, exercised and enhanced. The company is building BinoviTM, a universal, collaborative care platform that integrates software, hardware, data and the expert knowledge of vision care professionals to help patients on a global scale. Learn more at www.eyecarrot.com

On behalf of the Board of Directors

Adam Cegielski

President | CEO

Telephone: 1.855.416.7158 - 416.943.6271

Forward looking information

Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2019 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.